$9.270
+0.152 (+1.64%)收盘时
价格预测
在 App 中打开以解锁更长周期的预测。
RNAC 相似图表分析预测
Alphio's RNAC stock price prediction model matches the current Cartesian Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $9.19 (-0.84%). The 1-week path is $9.36 (+1.02%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
该买入 Cartesian Therapeutics Inc 股票吗?
Cartesian Therapeutics Inc is a good buy right now due to its recent strategic licensing deal that has driven the stock up over 30%, indicating strong market confidence. The current price is $9.60, which is significantly lower than the analyst price target of $25, suggesting substantial upside potential. Additionally, the company has a gross margin of 100%, showing strong profitability potential on revenues. However, a key risk is the forward P/E ratio of 25.06, indicating that the stock may be overvalued relative to its earnings potential in the near term.
RNAC 股价于 Friday 收于 $9.27,此前上涨 +1.64%
Cartesian Therapeutics Inc (RNAC) last closed at $9.27, gaining +1.64%. These facts feed the 1-day and 1-week RNAC price prediction above.
预测驱动因素
Cartesian Therapeutics Inc(RNAC)的预测驱动因素综合了相似的图表形态、季节性与移动平均线。
Similar patterns
Bearish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bullish
相似图表形态
近期走势与 RNAC 最接近的股票,按相似度排序。
RNAC 季节性分析
Historically the probability of a positive September return for RNAC is 8.89%. January offers the highest probability of a positive month at 85.25%, while September is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。